VEGF165 and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo

I. Wilcke, J. A. Lohmeyer, S. Liu, A. Condurache, S. Krüger, P. Mailänder, H. G. Machens

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Background: Angiogenesis can be enhanced by several growth factors, like vascular endothelial growth factor-165 (VEGF165) and basic fibroblast growth factor (bFGF). Delayed release of such growth factors could be provided by incorporation of growth factors in fibrin matrices. In this study, we present a slow release system for VEGF165 and bFGF in fibrin sealant. Materials and methods: In vitro: Pieces of Integra™ matrix of 15 mm in diameter were prepared. Integra™ matrices were divided into four groups (A=control; B=fibrin sealant; C=fibrin sealant+growth factors; D=growth factors). In vivo: The bioartificial dermal templates were transplanted into a full-skin defect of the back of nu-nu mice. Four different groups included each six matrices at 2 and 4 weeks. Results: In vitro: In groups C and D, continuous release of VEGF165 and bFGF was eminent. The incorporation of growth factors into fibrin sealant evoked a prolonged growth factor release (p<0.05). In vivo: A significantly higher amount of vessels was quantified in groups C and D compared to groups A and B (p<0.001). Conclusions: A model of slow protein release by combining VEGF165 and bFGF with fibrin sealant was produced. This model resulted in a prolonged bioavailability of growth factors in vivo for functional purposes. Fibrin and collagen can release growth factors in vivo and induce significant and faster neovascularisation in bioartificial dermal templates.

Original languageEnglish
Pages (from-to)305-314
Number of pages10
JournalLangenbeck's Archives of Surgery
Volume392
Issue number3
DOIs
StatePublished - May 2007
Externally publishedYes

Keywords

  • Angiogenesis
  • Matrix vascularisation
  • Protein-based therapy
  • Slow release system
  • VEGF and bFGF

Fingerprint

Dive into the research topics of 'VEGF165 and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo'. Together they form a unique fingerprint.

Cite this